Synthetic immunogens for blood stage malaria vaccine against plasmodium falciparum
Researchers have engineered synthetic vaccine immunogens containing key epitopes that elicit potent growth-inhibitory antibodies against malaria targets RH5 and CyRPA, including PfRH5-34EM, PfRH5-top and PfCyRPA-BD.
Applications: Synthetic polypeptides, treatment of malaria, prevention of malaria
| Features | Benefits |
|---|---|
| Novel, rationally designed synthetic immunogens targeting a specific region of RH5 or CyPRA to which most growth-neutralising antibodies bind | Overcomes the mixed immune response that is typically elicited when RH5 or CyRPA immunogens are used for vaccination |
| Use of structure-guided design to ensure optimised folding of the specified region | Presents the most effective epitope to the immune system |
| Immunogen series is validated and shown to be efficacious in a pre-clinical rat model | Generates a higher quality antibody response when used for immunisation compared to current vaccines |
| Could be used by itself, as part of sequence of immunisations with other immunogens or as part of a multi-stage vaccine program | Adaptability in vaccine delivery and program design |
Awaiting patent and Available For
- Co-development
- Licensing